US pharm major Eli Lilly (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase III trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin
1 To further understand what factors might influence whether patients were likely to maintain, regain, or lose more weight, we studied 25,552 patients prescribed semaglutide and 33,456 patients prescribed liraglutide for at least 90 days continuously between January 1, 2017, and February 1, 2023
Pen-injector specifics: Once you puncture a cartridge with a pen needle, most manufacturers rate the in-use shelf life at 28 days at 2 to 8 C
Fact These medications influence multiple metabolic signals including appetite regulation, digestion, and blood sugar balance
If its not the right time or option, dont worry
Structural tissue remodeling continues through weeks eight to twelve, with objective imaging improvements typically visible at the eight-week mark when applicable